SPARK Norway Educational Forum: Market and competitor analysis

SPARK Norway Educational Forum are monthly open meetings organized by UiO:Life Science and SPARK Norway partners.

Building a prosperous company is all about being one step ahead of your competitors and businesses that do not care about competition eventually disappear.

By doing market and competitor analysis you keep your finger on the pulse of your industry and thereby you can choose the best strategies to maximize your advantages. This is a critical part of your entire marketing plan.

Programme

Learn more about how to do good market and competitor analysis and how this will help you to develop the strategies to succeed in the market from two experienced life science professionals.
 

Emilie LassonImage may contain: Smile, Jaw, Happy, Monochrome photography, Throat.
Senior Vice President, Project Management
NorthSea Therapeutics B.V

Emilie has 25 years experience from pharmaceutical- life science- and diagnostics industry. She has held several managerial and executive positions in companies like Life Technologies (now ThermoFisher), Genetic Analysis AS and Sero AS, in addition to serving at several boards.

Her expertise is in managing complex development projects, and commercialization of products and/or technologies in addition to leadership of departments and complex project teams.

Emilie holds a PhD in chemistry from university of Utah and University of Oslo.

Jonas HallénImage may contain: Person, Forehead, Nose, Smile, Eyebrow.
Chief Medical & Development Officer  
Arxx Therapeutics

Before co-founding Arxx, Jonas had a 10-year career in drug development and medical roles in the pharmaceutical industry at Boehringer Ingelheim, Pronova BioPharma and Novartis.

Amongst other things Jonas was part of the team at Boehringer Ingelheim that launched Pradaxa – the first novel oral anticoagulant approved for stroke prevention in atrial fibrillation and he was project lead at Pronova for the drug development team that took icosabutate, a lipid lowering agent with powerful anti-inflammatory and anti-fibrotic effects, through clinical proof-of-concept.

He is passionate about drug development and greatly enjoys the scientific exploration of novel therapeutic concepts to improve human life.

Jonas holds an MD from the University of Copenhagen and a PhD in cardiovascular disease from the University of Oslo.

Organizer

UiO:Life Science
Published Feb. 1, 2021 1:06 PM - Last modified Nov. 4, 2021 9:27 AM